Peking University Cancer Hospital
Peking University Cancer Hospital
Beijing, Beijing Municipality, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | Oligometastatic Disease; Unresectable Hepatocellular Carcinoma | Recruiting | Phase 2 | 2023-06-23 | NCT05917431 |